Comparative sequencing study of mismatch repair and homology‐directed repair genes in endometrial cancer and breast cancer patients from Kazakhstan
2025

Study of Gene Variants in Endometrial and Breast Cancer Patients from Kazakhstan

Sample size: 520 publication 10 minutes Evidence: moderate

Author Information

Author(s): Zheng Ying, Vdovichenko Natalia, Schürmann Peter, Ramachandran Dhanya, Geffers Robert, Speith Lisa‐Marie, Bogdanova Natalia, Enßen Julia, Dubrowinskaja Natalia, Yugay Tatyana, Yessimsiitova Zura Berkutovna, Turmanov Nurzhan, Hillemanns Peter, Dörk Thilo

Primary Institution: Hannover Medical School

Hypothesis

What is the distribution of pathogenic variants in mismatch repair and homology-directed repair genes among endometrial and breast cancer patients in Kazakhstan?

Conclusion

Pathogenic variants in mismatch repair and homology-directed repair genes occur at significant frequencies in both breast and endometrial cancer patients from Kazakhstan.

Supporting Evidence

  • 10 endometrial cancer patients (2.9%) carried pathogenic variants in MMR genes.
  • 14 endometrial cancer patients (4.1%) carried pathogenic variants in HDR genes.
  • 8 breast cancer patients (4.5%) had pathogenic variants in MMR genes.
  • 12 breast cancer patients (6.7%) had pathogenic variants in HDR genes.

Takeaway

This study looked at patients with endometrial and breast cancer in Kazakhstan to see if they had certain gene changes that could affect their cancer. They found that many patients had these changes.

Methodology

The study involved targeted next-generation sequencing of genes related to mismatch repair and homology-directed repair in patients with endometrial and breast cancer.

Potential Biases

Potential bias due to the unselected nature of the patient cohort and the ethnic diversity of the population.

Limitations

The study lacked sequencing data for a healthy population and did not include extensive tumor characterization.

Participant Demographics

Patients were of Asian (mainly Altaic) or European (mainly Russian) ancestry, with a median age of 60 for endometrial cancer and 52 for breast cancer.

Statistical Information

P-Value

p=0.0009

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/ijc.35215

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication